Proceedings · Session S-998 · filed November 17, 2026
Translational ScienceSession paper
FDA Approves Pimicotinib for TGCT on 56% Response Rate
FDA approved pimicotinib for TGCT on a 56% response rate in MANEUVER; the Project Orbis review with EMA observation signals tighter, concurrent global launch planning for sponsors.
By Sophie Lindqvist3 min read536 words
Summary
- FDA approved pimicotinib (Pimjetmi) for symptomatic TGCT on November 10, 2026.
- MANEUVER trial showed 56% ORR (95% CI, 42–68) vs 3.2% for placebo at Week 25.
- Recommended dose is 50 mg orally once daily; 77% of responders maintained response at least 12 months.
- Review ran under Project Orbis with the EMA as official observer; applicant used the voluntary Assessment Aid.
- China's CDE accepted Merck KGaA's pimicotinib application under priority review in June 2025.
![<![CDATA[Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review]]>](/media/c3/c336b35817343416.1280.webp)
The FDA approved Pimjetmi (pimicotinib) on November 10, 2026 for adults with symptomatic tenosynovial giant cell tumor (TGCT) whose surgical resection risks worsening functional limitation or severe morbidity, basing the decision on a 56% overall response rate in the phase 3 MANEUVER trial. The once-daily oral kinase inhibitor carried fast track and breakthrough therapy designations and went through Project Orbis, the FDA Oncology Center of Excellence framework that runs concurrent reviews with international regulators, with the EMA participating as an official observer.
The approval gives clinicians a second targeted oral option for tumors that cannot be safely removed. In February 2025, the FDA approved vimseltinib (Romvimza) for the same indication, on the strength of the phase 3 MOTION trial.
What did the MANEUVER trial show?
The pivotal evidence comes from MANEUVER (NCT05804045), a double-blind, randomized (2:1), placebo-controlled, international trial. Eligible patients had symptomatic TGCT with at least one measurable lesion of 2 cm or larger.
The measured results at Week 25:
- Overall response rate by blinded independent central review: 56% for pimicotinib (95% CI, 42–68) versus 3.2% for placebo (95% CI, 0.1–17).
- Median duration of response: not reached.
- Among responders, 32 patients (91%) held a response for at least 6 months; 27 (77%) for at least 12 months.
The pimicotinib arm also showed statistically significant improvements across prespecified patient-reported and functional endpoints. These covered active range of motion of the affected joint measured by goniometry, worst pain on the brief pain inventory worst pain numeric rating scale, and the PROMIS physical function T-score.
The safety profile requires monitoring. The most common adverse reactions, each above 20%, were pruritus, rash, face edema, periorbital edema, fatigue, nausea, headache, and peripheral edema. Laboratory abnormalities above 30% included increases in creatine phosphokinase, lactate dehydrogenase, aspartate aminotransferase, lipase, cholesterol, amylase, and alanine aminotransferase. Prescribing information carries warnings for hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without affecting renal function. The recommended dose is 50 mg orally once daily, with or without food.
Why does the review pathway matter?
The applicant also used the Assessment Aid, a voluntary submission designed to make the FDA's assessment more efficient. Several international regulators reviewed the application alongside the FDA, and their applications may still be in submission or under review.
This pattern is now common in oncology. GSK's recent Jemperli (dostarlimab) filing, accepted for priority review on August 24, 2026 for dMMR/MSI-H locally advanced rectal cancer, also went through Project Orbis. For development and regulatory affairs teams, coordinated multimarket review is becoming the default, which means planning filings and manufacturing readiness for all regions at once rather than market by market. Project Orbis timelines compress global launches, pushing manufacturers to coordinate batch release and manage region-specific labeling.
Pimicotinib was already moving through other regulators. In June 2025, China's Center for Drug Evaluation accepted Merck KGaA's marketing application under priority review.
With several regulators now examining the same oral small molecule in parallel, supply readiness, label harmonization, and postapproval change management become immediate operational priorities for the sponsor.
The MANEUVER durability data, with median duration of response still unreached, will continue to mature as postmarketing follow-up accumulates.
via pharmtech.com (Source)
Filed under
- pimicotinib
- tenosynovial-giant-cell-tumor
- fda-approval
- maneuver-trial
- project-orbis
More from Sophie Lindqvist
Show full bio
Correspondent covering money, funding and market shifts around research and development at Hypothesis Wire.
242 articles